Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium
Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium
Publication date :
January 2017
Journal title :
PLoS ONE
eISSN :
1932-6203
Publisher :
Public Library of Science, San Franscisco, United States - California
Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57:1333-1342. doi: 10.1002/hep.26141 PMID: 23172780
Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008; 47:1128-1135. doi: 10.1002/hep.22165 PMID: 18318441
Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374. doi: 10.1002/hep.22759 PMID: 19330875
Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9:509-516. doi: 10.1016/j.cgh.2011.03.004 PMID: 21397729
van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308:2584-2593. doi: 10.1001/jama.2012.144878 PMID: 23268517
Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-1493. doi: 10.1056/NEJMoa1316366 PMID: 24725238
Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-1898. doi: 10.1056/NEJMoa1402454 PMID: 24725239
Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594-1603. doi: 10.1056/NEJMoa1315722 PMID: 24720703
Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879-1888. doi: 10.1056/NEJMoa1402355 PMID: 24720702
Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M,et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1604-1614. doi: 10.1056/NEJMoa1401561 PMID: 24720679
Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384:1756-1765. doi: 10.1016/S0140-6736(14)61036-9 PMID: 25078309
European association for the study of the liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63:199-236. doi: 10.1016/j.jhep.2015.03.025 PMID: 25911336
AASLD/IDSA HCV guidance panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62:932-954. doi: 10.1002/hep.27950 PMID: 26111063
Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S, et al. Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in HCV Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study. Hepatology 2016 Jan 22.
Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, et al; HCV-TARGET Study Group. Effectiveness of Simeprevir plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection. Gastroenterology 2016; 150:419-429. doi: 10.1053/j.gastro.2015.10.013 PMID: 26497081
Aqel BA, Pungpapong S, Leise M, Werner KT, Chervenak AE, Watt KD, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology 2015; 62:1004-1012. doi: 10.1002/hep.27937 PMID: 26096332
Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 2014; 39:137-147. doi: 10.1111/apt.12551 PMID: 24251930
Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008; 47:1371-1383. doi: 10.1002/hep.22127 PMID: 18240152
Nicot F, Legrand-Abravanel F, Sandres-Saune K, Boulestin A, Dubois M, Alric L, et al. Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France. J Gen Virol 2005; 86:107-114. doi: 10.1099/vir.0.80409-0 PMID: 15604436
Kamal SM. Hepatitis C genotype 4 therapy: increasing options and improving outcomes. Liver Int 2009; 29:39-48. doi: 10.1111/j.1478-3231.2008.01930.x PMID: 19207965
Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, et al. Management of hepatitis C genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54:1250-1262. doi: 10.1016/j.jhep.2010.11.016 PMID: 21316497
Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout egypt. J Infect Dis 2000; 182:698-707. doi: 10.1086/315786 PMID: 10950762
Al Ashgar HI, Khan MQ, Al-Ahdal M, Al Thawadi S, Helmy AS, Al Qahtani A et al. Hepatitis C genotype 4: genotypic diversity, epidemiological profile, and clinical relevance of subtypes in Saudi Arabia. Saudi J Gastroenterol 2013; 19:28-33. doi: 10.4103/1319-3767.105920 PMID: 23319035
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-1887. doi: 10.1056/NEJMoa1214853 PMID: 23607594
Wehmeyer MH, Jordan S, Lüth S, Hartl J, Stoehr A, Eißing C, et al. Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection. Dig Liver Dis 2015; 47:811-814. doi: 10.1016/j.dld.2015.05.018 PMID: 26091766
Moreno C, Hezode C, Marcellin P, Bourgeois S, Francque S, Samuel D, et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. J Hepatol 2015; 62:1047-1055. doi: 10.1016/j.jhep.2014.12.031 PMID: 25596313
Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350. PMID: 15685546
Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Filice G, Filice C; Liver Fibrosis Study Group. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology 2012; 56:2125-2133. doi: 10.1002/hep.25936 PMID: 22767302
Holmberg SD, Lu M, Rupp LB, Lamerato LE, Moorman AC, Vijayadeva V, et al; Chronic Hepatitis Cohort Study (CHeCS) Investigators. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis 2013; 57:240-246. doi: 10.1093/cid/cit245 PMID: 23592832
Belgian HCV therapy guidance. Belgian Association for the Study of the Liver BASL. http://www.basl.be
Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R,et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A Phase 3 study (OPTIMIST-2). Hepatology 2016; 64:360-9. doi: 10.1002/hep.28422 PMID: 26704148
Doss W, Shiha G, Hassany M, Soliman R, Fouad R, Khairy M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 2015; 63:581-585. doi: 10.1016/j.jhep.2015. 04.023 PMID: 25937436
Willemse SB, Baak LC, Kuiken SD, van der Sluys Veer A, Lettinga KD, van der Meer JT et al. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life. J Viral Hepat. 2016; 23:950-954 doi: 10.1111/jvh.12567 PMID: 27405785
Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, et al.Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis 2015; 15:1049-1054. doi: 10.1016/S1473-3099(15)00157-7 PMID: 26187031
Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al; SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016; 16:685-697. doi: 10.1016/S1473-3099(16)00052-9 PMID: 26907736
Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med 2015; 163:1-13. doi: 10.7326/M15-0785 PMID: 25909356
Asselah T, Reesink HW, Gerstoft J, de Ledinghen V, Pockros PJ, Robertson M et al. High efficacy of grazoprevir and elbasvir with and without ribavirin in 103 treatment-naive and experienced patients with HCV genotype 4 infection: a pooled analysis. Hepatology 2015 suppl;340A
Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N,et al; ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015; 373:2599-2607. doi: 10.1056/NEJMoa1512610 PMID: 26571066
Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al; ASTRAL-4 Investigators. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med 2015; 373:2618-2628. doi: 10.1056/NEJMoa1512614 PMID: 26569658
Asselah T, Hézode C, Qaqish RB, Elkhashab M, Hassanein T, Papatheodoridis G et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Lancet Gastro hepatol 2016; 1:25-35
Food and Drug Administration (FDA). Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie, 2015. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm468634. Accessed 8 February 2016.
